Fmr LLC Ardelyx, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Ardelyx, Inc. stock. As of the latest transaction made, Fmr LLC holds 53,796 shares of ARDX stock, worth $310,402. This represents 0.0% of its overall portfolio holdings.

Number of Shares

53,796

Previous 49,562 8.54%

Holding current value

$310,402

Previous $361,000 10.25%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$5.89 - $9.31 $24,938 - $39,418	4,234 Added 8.54%	53,796 $398,000
Q1 2024 May 13, 2024	BUY	$6.05 - $9.74 $196,413 - $316,209	32,465 Added 189.89%	49,562 $361,000
Q4 2023 Feb 13, 2024	SELL	$3.29 - $6.64 $26,747 - $53,983	-8,130 Reduced 32.23%	17,097 $106,000
Q3 2023 Nov 13, 2023	BUY	$3.3 - $4.83 $36,045 - $52,758	10,923 Added 76.36%	25,227 $102,000
Q2 2023 Aug 11, 2023	BUY	$3.23 - $4.95 $27,684 - $42,426	8,571 Added 149.5%	14,304 $48,000
Q1 2023 May 11, 2023	BUY	$2.68 - $4.79 $10,789 - $19,284	4,026 Added 235.85%	5,733 $27,000
Q4 2022 Feb 13, 2023	SELL	$1.22 - $2.85 $12,108 - $28,286	-9,925 Reduced 85.32%	1,707 $4,000
Q3 2022 Nov 10, 2022	BUY	$0.59 - $1.44 $4,828 - $11,784	8,184 Added 237.35%	11,632 $14,000
Q2 2022 Aug 12, 2022	SELL	$0.51 - $1.17 $5,281 - $12,116	-10,356 Reduced 75.02%	3,448 $2,000
Q1 2022 May 13, 2022	BUY	$0.65 - $1.18 $8,972 - $16,288	13,804 New	13,804 $15,000
Q3 2021 Nov 15, 2021	SELL	$1.27 - $8.17 $123,309 - $793,257	-97,094 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$6.55 - $8.98 $635,965 - $871,904	97,094 New	97,094 $735,000

Others Institutions Holding ARDX

# of Institutions

209

Shares Held

144M

Call Options Held

1.01M

Put Options Held

1.43M

View Full List

About ARDELYX, INC.

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $892M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

More about ARDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account